Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
Zhejiang-based GNMI Expands Overseas: Hangzhou Becomes a New Starting Point for the China-German Industrial Synergies
Hangzhou, China, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of…
